Esperion Therapeutics (ESPR) Change in Receivables (2020 - 2025)
Historic Change in Receivables for Esperion Therapeutics (ESPR) over the last 6 years, with Q3 2025 value amounting to $11.2 million.
- Esperion Therapeutics' Change in Receivables rose 5050.91% to $11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.2 million, marking a year-over-year increase of 10299.19%. This contributed to the annual value of $31.6 million for FY2024, which is 11434.47% up from last year.
- According to the latest figures from Q3 2025, Esperion Therapeutics' Change in Receivables is $11.2 million, which was up 5050.91% from $26.5 million recorded in Q2 2025.
- In the past 5 years, Esperion Therapeutics' Change in Receivables ranged from a high of $26.5 million in Q2 2025 and a low of -$144000.0 during Q3 2021
- For the 5-year period, Esperion Therapeutics' Change in Receivables averaged around $5.6 million, with its median value being $4.4 million (2023).
- In the last 5 years, Esperion Therapeutics' Change in Receivables crashed by 10501.39% in 2021 and then surged by 263125.0% in 2022.
- Quarter analysis of 5 years shows Esperion Therapeutics' Change in Receivables stood at $1.2 million in 2021, then skyrocketed by 83.01% to $2.2 million in 2022, then soared by 162.1% to $5.9 million in 2023, then soared by 109.81% to $12.3 million in 2024, then decreased by 8.8% to $11.2 million in 2025.
- Its last three reported values are $11.2 million in Q3 2025, $26.5 million for Q2 2025, and $1.2 million during Q1 2025.